fashion -WSS

fashion

author：focus 2025-09-27 17:02:29 - browse：6267

The Food and Drug Administration on Friday approved a new, rapid-acting medicine made by Sage Therapeutics to treat postpartum depression, the first oral treatment for the condition. But the agency denied the company’s application for an indication for major depression, a much larger potential market.

The drug, which will be sold under the brand name Zurzuvae, is not meant to be taken chronically. Patients take it orally for 14 days. In two clinical trials, the drug was found to significantly improve depressive symptoms more than a placebo. The effect was maintained for four weeks after treatment.

“Maternal mental health has been sidelined for far too long, but today’s approval of Zurzuvae helps to change that. Women have been waiting for an oral medicine that can specifically and rapidly improve the symptoms of PPD and we are proud to be able to deliver that,” said Barry Greene, Sage’s CEO, in a press release.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： In the gardens at Boston Children's Hospital, families find sanctuary

focus

WSS

Merck to acquire Harpoon Therapeutics for $680 million

A preacher's new calling: Diversifying neuroscience research

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

STAT Virtual Event: JPM Recap, Live!

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

A preacher's new calling: Diversifying neuroscience research

Wikipedia

fashion

knowledge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Nonprofit, backed by Microsoft, to certify AI tools in health care

George Santos makes 1st court appearance after pleading not guilty to 13 counts

What it's like to live with paralysis for one psychologist

What does generative AI mean for health care? We asked experts

Why patients can’t get everything they want on drug pricing

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What to watch for from Zogenix and Amicus clinical trials

Trump demands the U.S. pay no more for drugs than other countries … again

Arena BioWorks launches in Cambridge to speed drug discovery

leisure time

UHS says company favors patients whose insurance pays more

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Search called off for baby washed away in Pennsylvania flash flood

The haunting brain science of long Covid

Physician assistants need a new name. Here's what it should be

Biogen says it will cut costs by $700 million, slash 1,000 jobs

hotspot

focus

focus

knowledge